Isatuximab API is a pharmaceutical-grade humanized IgG1 monoclonal antibody that selectively targets the CD38 receptor, a cell surface glycoprotein highly expressed on multiple myeloma cells. Binding to CD38 induces tumor cell death through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis.
Isatuximab is approved for use in combination with other antimyeloma therapies for the treatment of relapsed or refractory multiple myeloma in adult patients. It is administered as an intravenous infusion and represents an important targeted immunotherapy in hematologic oncology.
Manufactured under WHO-GMP-certified biopharmaceutical facilities, our Isatuximab API is produced using advanced recombinant biotechnology processes to ensure exceptional purity, biological activity, stability, and batch-to-batch consistency. Every batch undergoes comprehensive quality testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Isatuximab API is used in injectable biopharmaceutical formulations for the treatment of relapsed or refractory multiple myeloma in combination with other anticancer agents.
Isatuximab binds to the CD38 protein on myeloma cells, triggering immune-mediated tumor cell destruction through ADCC, CDC, ADCP, and apoptosis.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Isatuximab API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing worldwide.
Get Bulk Quote via WhatsApp